Table 4 Results of subgroup meta- analyses for Campylobacter and irritable bowel syndrome from studies published prior to July 2011
Variable | Summary Estimate | Lower 95% CI | Upper 95% CI | I2 | Number of outcome measures |
|---|---|---|---|---|---|
Overall Estimate | 4.01% | 1.41% | 10.88% | 99.2% | 10 |
Study Directionality | Â | Â | Â | Â | Â |
Prospective | 8.64% | 6.36% | 11.66% | 83.7% | 8 |
Retrospective | 0.15% | 0.0048% | 4.75% | 99.4 | 2 |
Method of Assessing Sequelae | Â | Â | Â | Â | Â |
Self-reported | 5.27% | 0.84% | 26.84% | 68.0% | 2 |
Self-reported based on validated scale* | 9.94% | 7.90% | 12.44% | 73.6% | 6 |
Based on medical records | 0.15% | 0.0048% | 4.75% | 99.4% | 2 |
Group Size | Â | Â | Â | Â | Â |
Small | 13.56% | 5.76% | 28.74% | 0.0% | 2 |
Medium | 4.96% | 1.43% | 15.79% | 91.2% | 2 |
Large | 9.92% | 7.52% | 12.98% | 83.6% | 4 |
Extra large | 0.15% | 0.0048% | 4.75% | 99.4 | 2 |